Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/June-2018/screenshot_152.jpg)
TAILORx: Most women with intermediate risk ER+ breast cancer can safely skip chemo
- Author:
- Susan London
CHICAGO - Lead study author Dr. Joseph A. Sparano discusses the implications of the new data for decision-making and future plans for the tumor...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/June-2018/Jotte_Robert_M_CO_web.jpg)
Atezolizumab has PFS benefit in first-line squamous NSCLC
- Author:
- Susan London
CHICAGO – Atezolizumab prolongs PFS by about a month, and patients derived benefit regardless of the level of PD-L1 expression.
Video
![Dr. Jeoffrey Oxnard](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/June-2018/oxnard.jpg)
A blood test to detect lung cancer inches toward the clinic
- Author:
- Susan London
CHICAGO - Dr. Geoffrey R. Oxnard discusses interim results from the Circulating Cell-Free Genome Atlas project and ongoing work to bring the blood...
Video
![Dr. Yezefski](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/June-2018/yezefski.jpg)
Metastatic colorectal cancer chemo costs double in Washington vs. British Columbia
- Author:
- Susan London
CHICAGO - Dr. Todd Yezefski discusses the drivers of cost disparities and implications for policy makers.
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/June-2018/head_neck.jpg)
Head and neck cancers: Women less commonly receive intensive chemo
- Author:
- Susan London
CHICAGO - Senior study author Dr. Jed A. Katzel discusses ongoing research to understand the reasons behind the apparent disparities.
News
CBT-I bests acupuncture for treating insomnia among cancer survivors
- Author:
- Susan London
In a randomized trial, both CBT-I and acupuncture reduced insomnia severity among cancer survivors, but the former had the edge.
News
Uptake of lung cancer screening is exceedingly low
- Author:
- Susan London
The annual rate of LDCT screening for lung cancer among eligible current and former heavy smokers was just 1.9% in 2016 across the United States...
News
New remote monitoring system lessens symptoms in head and neck cancer
- Author:
- Susan London
The CYCORE system, which harnesses wireless sensor and mobile technology to remotely monitor vitals and symptoms, reduces symptom severity in...
News
Adjuvant trastuzumab for breast cancer: 6 months may suffice
- Author:
- Susan London
Disease-free survival was similarly high whether women received adjuvant trastuzumab for the current standard of 12 months or for just 6 months....
News
New regimens for youth with T-cell malignancies yield best outcomes yet
- Author:
- Susan London
More than 8 in 10 youth were still alive and free of disease 4 years after starting combinations of methotrexate and/or nelarabine with chemo.
News
Upfront NGS testing of metastatic NSCLC saves money, time
- Author:
- Susan London
NGS at the time of metastatic NSCLC diagnosis could save millions of dollars relative to more conservative testing strategies, and results become...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/March-2018/Jones_1_web.jpg)
Emerging data help inform immunotherapy for urothelial cancer
- Author:
- Susan London
Atezolizumab had a marked survival benefit vs. chemotherapy in patients with TMB-high, PD-L1–positive urothelial tumors.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/March-2018/Bruix_Jordi_SPAIN_web.jpg)
New treatment options emerge for intermediate, advanced HCC
- Author:
- Susan London
SAN FRANCISCO – Two new therapies that target VEGF signaling are efficacious and may expand the treatment for intermediate and advanced HCC.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/February-2018/Hussain_Maha_CHICAGO_web.jpg)
Enzalutamide shines in nonmetastatic castration-resistant prostate cancer
- Author:
- Susan London
SAN FRANCISCO - Metastasis-free survival was 36.6 months with enzalutamide and 14.7 months with placebo.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/February-2018/Coen_John_J_providence_web.jpg)
Bladder cancer: Two chemoradiation therapy regimens on par for muscle-invasive disease
- Author:
- Susan London
Primary results were comparable in the NRG/RTOG 0712 trial, but one regimen is more convenient.